NL-OMON42154已完成4 期
Precision dosing of infliximab (IFX): the efficacy and economic effect of *precision dosing* of maintenance treatment with IFX in comparison with standard IFX maintenance treatment in inflammatory bowel disease. - Precision dosing of infliximab
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •Diagnosis of CD or UC based on endoscopy and pathology
- •18 years or older
- •Clinical remission, based on a Harvey Bradshaw Index (HBI) score *4 or a Partial Mayo (PM) score *2, for CD and UC
- •Scheduled IFX maintenance treatment, regardless of interval/dosing
排除标准
- •A history of stenotic IBD requiring dilatation and or resectional surgery in the past year
研究者
相似试验
进行中(未招募)
1 期
EFFICACI : EFFicacy of intravenous Infliximab versus vedolizumab after failure of subCutaneous Anti-TNF in patients with UlCerative colitis : A double blinded Randomized Clinical Trial.lcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-002673-21-FRCentre Hospitalier Universitaire de Rennes150
已完成
不适用
Study of the pharmacokinetics of Infliximab (IFX) in moderate to severe Ulcerative ColitisInflammatory Bowel Disease10017969Ulcerative ColitisNL-OMON37516Academisch Medisch Centrum20
进行中(未招募)
不适用
Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosingSarcoidosisEUCTR2014-002224-26-NLSt. Antonius Hospital
撤回
4 期
A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment1002766510024967SarcoidosisNL-OMON42033Sint Antonius Ziekenhuis70
进行中(未招募)
不适用
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEModerate to severe plaque PsoriasisMedDRA version: 11.0Level: LLTClassification code 10037153Term: <Manually entered code. Term in E.1.1>EUCTR2008-000454-12-GRSchering Plough Research Institute, a Division of Schering Corporation200
